REFERENCES

Abbas, A. K., Lichtman, A. H., & Pillai, S. (2020). *Basic immunology: Functions and disorders of the immune system*. Elsevier.

Aftab, S. O., Ghouri, M. Z., Masood, M. U., Haider, Z., Khan, Z., Ahmad, A., & Munawar, N. (2020). Analysis of SARS-COV-2 RNA-dependent RNA polymerase as a potential therapeutic drug target using a computational approach. *Journal of Translational Medicine*, *18*(1). https://doi.org/10.1186/s12967-020-02439-0

Alefishat, E., Jelinek, H. F., Mousa, M., Tay, G. K., & Alsafar, H. S. (2022). Immune response to SARS-COV-2 variants: A focus on severity, susceptibility, and preexisting immunity. *Journal of Infection and Public Health*, *15*(2), 277–288. https://doi.org/10.1016/j.jiph.2022.01.007

Altmann, D. M., & Boyton, R. J. (2020). SARS-COV-2 T cell immunity: Specificity, function, durability, and role in protection. *Science Immunology*, *5*(49). https://doi.org/10.1126/sciimmunol.abd6160

Almofti, Y. A., Abd-elrahman, K. A., & Eltilib, E. E. (2021). Vaccinomic approach for novel multi epitopes vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-COV-2). *BMC Immunology*, *22*(1). https://doi.org/10.1186/s12865-021-00412-0

Aran, D., Beachler, D. C., Lanes, S., & Overhage, J. M. (2020). Prior presumed coronavirus infection reduces COVID-19 risk: A cohort study. *The Journal of infection*, *81*(6), 923–930. https://doi.org/10.1016/j.jinf.2020.10.023

Beans, C. (2022). Researchers getting closer to a “universal” flu vaccine. *Proceedings of the National Academy of Sciences*, *119*(5). https://doi.org/10.1073/pnas.2123477119

Beretta, A., Cranage, M., & Zipeto, D. (2020). Is cross-reactive immunity triggering COVID-19 immunopathogenesis? *Frontiers in Immunology*, *11*. https://doi.org/10.3389/fimmu.2020.567710

Boechat, J. L., Chora, I., Morais, A., & Delgado, L. (2021). The immune response to SARS-COV-2 and COVID-19 immunopathology – current perspectives. *Pulmonology*, *27*(5), 423–437. https://doi.org/10.1016/j.pulmoe.2021.03.008

Bui, H.-H., Sidney, J., Dinh, K., Southwood, S., Newman, M. J., & Sette, A. (2006). Predicting population coverage of T-cell epitope-based diagnostics and vaccines. *BMC Bioinformatics*, *7*(1). https://doi.org/10.1186/1471-2105-7-153

Bui, H.-H., Sidney, J., Li, W., Fusseder, N., & Sette, A. (2007). Development of an epitope conservancy analysis tool to facilitate the design of epitope-based diagnostics and vaccines. *BMC Bioinformatics*, *8*(1). https://doi.org/10.1186/1471-2105-8-361

Calis, J. J., Maybeno, M., Greenbaum, J. A., Weiskopf, D., De Silva, A. D., Sette, A., Keşmir, C., & Peters, B. (2013). Properties of MHC class I presented peptides that enhance immunogenicity. *PLoS Computational Biology*, *9*(10). https://doi.org/10.1371/journal.pcbi.1003266

Cascella, M., Rajnik, M., Aleem, A., Dulebohn, S. C., & Napoli, R. D. (2021). *Features, evaluation, and treatment of coronavirus (COVID-19)*. StatPearls [Internet]. Retrieved 2021, from https://www.ncbi.nlm.nih.gov/books/NBK554776/.

Deng, H., Yan, X., & Yuan, L. (2021). Human genetic basis of coronavirus disease 2019. *Signal Transduction and Targeted Therapy*, *6*(1). https://doi.org/10.1038/s41392-021-00736-8

Dhanda, S. K., Vir, P., & Raghava, G. P. S. (2013). Designing of interferon-gamma inducing MHC class-II binders. *Biology Direct*, *8*(1). https://doi.org/10.1186/1745-6150-8-30

Echeverría, G., Guevara, Á., Coloma, J., Ruiz, A. M., Vasquez, M. M., Tejera, E., & de Waard, J. H. (2021). Pre-existing T-cell immunity to SARS-CoV-2 in Unexposed healthy controls in Ecuador, as detected with A COVID-19 interferon-gamma RELEASE ASSAY. *International Journal of Infectious Diseases*, *105*, 21–25. https://doi.org/10.1016/j.ijid.2021.02.034

Erbelding, E. J., Post, D. J., Stemmy, E. J., Roberts, P. C., Augustine, A. D., Ferguson, S., Paules, C. I., Graham, B. S., & Fauci, A. S. (2018). A universal influenza vaccine: The strategic plan for the National Institute of Allergy and Infectious Diseases. *The Journal of Infectious Diseases*, *218*(3), 347–354. https://doi.org/10.1093/infdis/jiy103

Ferretti, A. P., Kula, T., Wang, Y., Nguyen, D. M. V., Weinheimer, A., Dunlap, G. S., Xu, Q., Nabilsi, N., Perullo, C. R., Cristofaro, A. W., Whitton, H. J., Virbasius, A., Olivier, K. J., Buckner, L. R., Alistar, A. T., Whitman, E. D., Bertino, S. A., Chattopadhyay, S., & MacBeath, G. (2020). Unbiased screens show CD8+ T cells of COVID-19 patients recognize shared epitopes in SARS-COV-2 that largely reside outside the spike protein. *Immunity*, *53*(5). https://doi.org/10.1016/j.immuni.2020.10.006

Forni, D., Cagliani, R., Clerici, M., & Sironi, M. (2017). Molecular Evolution of Human Coronavirus Genomes. *Trends in microbiology*, *25*(1), 35–48. https://doi.org/10.1016/j.tim.2016.09.001

Grifoni, A., Weiskopf, D., Ramirez, S. I., Mateus, J., Dan, J. M., Moderbacher, C. R., Rawlings, S. A., Sutherland, A., Premkumar, L., Jadi, R. S., Marrama, D., de Silva, A. M., Frazier, A., Carlin, A. F., Greenbaum, J. A., Peters, B., Krammer, F., Smith, D. M., Crotty, S., & Sette, A. (2020). Targets of T cell responses to SARS-COV-2 coronavirus in humans with covid-19 disease and unexposed individuals. *Cell*, *181*(7). https://doi.org/10.1016/j.cell.2020.05.015

Gustiananda, M. (2020). What do T cells see in SARS-CoV2? Immunoinformatics analysis to identify T cell epitopes from SARS- CoV2 ORF1ab polyprotein. *Indonesian Journal of Life Sciences*, *02*(01), 29–43.

Gustiananda, M., Sulistyo, B. P., Agustriawan, D., & Andarini, S. (2021). Immunoinformatics analysis of SARS-COV-2 orf1ab polyproteins to identify promiscuous and highly conserved T-cell epitopes to formulate vaccine for Indonesia and the World Population. *Vaccines*, *9*(12), 1459. https://doi.org/10.3390/vaccines9121459

Gonzalez-Galarza, F. F., McCabe, A., Santos, E. J. M. dos, Jones, J., Takeshita, L., Ortega-Rivera, N. D., Cid-Pavon, G. M. D., Ramsbottom, K., Ghattaoraya, G., Alfirevic, A., Middleton, D., & Jones, A. R. (2019). Allele frequency net database (AFND) 2020 update: Gold-standard data classification, open access genotype data and New Query Tools. *Nucleic Acids Research*. https://doi.org/10.1093/nar/gkz1029

Haider, N., Rothman-Ostrow, P., Osman, A. Y., Arruda, L. B., Macfarlane-Berry, L., Elton, L., Thomason, M. J., Yeboah-Manu, D., Ansumana, R., Kapata, N., Mboera, L., Rushton, J., McHugh, T. D., Heymann, D. L., Zumla, A., & Kock, R. A. (2020). COVID-19-Zoonosis or Emerging Infectious Disease?. *Frontiers in public health*, *8*, 596944. https://doi.org/10.3389/fpubh.2020.596944

Hewitt E. W. (2003). The MHC class I antigen presentation pathway: strategies for viral immune evasion. *Immunology*, *110*(2), 163–169. https://doi.org/10.1046/j.1365-2567.2003.01738.x

Holland, C. J., Cole, D. K., & Godkin, A. (2013). Re-directing CD4+ T cell responses with the flanking residues of MHC class II-bound peptides: The core is not enough. *Frontiers in Immunology*, *4*. https://doi.org/10.3389/fimmu.2013.00172

Hsu, J. C.-C., Laurent-Rolle, M., Pawlak, J. B., Wilen, C. B., & Cresswell, P. (2021). Translational shutdown and evasion of the innate immune response by SARS-COV-2 NSP14 protein. *Proceedings of the National Academy of Sciences*, *118*(24). https://doi.org/10.1073/pnas.2101161118

Jacob-Dolan, C., Feldman, J., McMahan, K., Yu, J., Zahn, R., Wegmann, F., Schuitemaker, H., Schmidt, A. G., & Barouch, D. H. (2021). Coronavirus-specific antibody cross-reactivity in rhesus macaques following SARS-COV-2 vaccination and infection. *Journal of Virology*, *95*(11). https://doi.org/10.1128/jvi.00117-21

Jungreis, I., Sealfon, R., & Kellis, M. (2021). SARS-COV-2 gene content and covid-19 mutation impact by comparing 44 sarbecovirus genomes. *Nature Communications*, *12*(1). https://doi.org/10.1038/s41467-021-22905-7

Koff, W. C., & Berkley, S. F. (2021). A universal coronavirus vaccine. *Science*, *371*(6531), 759–759. https://doi.org/10.1126/science.abh0447

Kundu, R., Narean, J. S., Wang, L., Fenn, J., Pillay, T., Fernandez, N. D., Conibear, E., Koycheva, A., Davies, M., Tolosa-Wright, M., Hakki, S., Varro, R., McDermott, E., Hammett, S., Cutajar, J., Thwaites, R. S., Parker, E., Rosadas, C., McClure, M., … Lalvani, A. (2022). Cross-reactive memory T cells associate with protection against SARS-COV-2 infection in COVID-19 contacts. *Nature Communications*, *13*(1). https://doi.org/10.1038/s41467-021-27674-x

Langton, D. J., Bourke, S. C., Lie, B. A., Reiff, G., Natu, S., Darlay, R., Burn, J., & Echevarria, C. (2021). The influence of HLA genotype on the severity of COVID-19 infection. *HLA*, *98*(1), 14–22. https://doi.org/10.1111/tan.14284

Lawton G. (2021). Sights set on universal vaccine. *New scientist (1971)*, *249*(3323), 8–9. https://doi.org/10.1016/S0262-4079(21)00302-X

Lee, C. H., Pinho, M. P., Buckley, P. R., Woodhouse, I. B., Ogg, G., Simmons, A., Napolitani, G., & Koohy, H. (2020). Potential CD8+ T cell cross-reactivity against SARS-COV-2 conferred by other coronavirus strains. *Frontiers in Immunology*, *11*. https://doi.org/10.3389/fimmu.2020.579480

Leone, P., Shin, E.-C., Perosa, F., Vacca, A., Dammacco, F., & Racanelli, V. (2013). MHC class I antigen processing and presenting machinery: Organization, function, and defects in tumor cells. *JNCI Journal of the National Cancer Institute*, *105*(16), 1172–1187. https://doi.org/10.1093/jnci/djt184

Lim, Y., Ng, Y., Tam, J., & Liu, D. (2016). Human Coronaviruses: A review of virus–host interactions. *Diseases*, *4*(4), 26. https://doi.org/10.3390/diseases4030026

Liu, D. X., Liang, J. Q., & Fung, T. S. (2021). Human Coronavirus-229E, -OC43, -NL63, and -HKU1 (*Coronaviridae*). *Encyclopedia of Virology*, 428–440. https://doi.org/10.1016/B978-0-12-809633-8.21501-X

Mateus, J., Grifoni, A., Tarke, A., Sidney, J., Ramirez, S. I., Dan, J. M., Burger, Z. C., Rawlings, S. A., Smith, D. M., Phillips, E., Mallal, S., Lammers, M., Rubiro, P., Quiambao, L., Sutherland, A., Yu, E. D., da Silva Antunes, R., Greenbaum, J., Frazier, A., … Weiskopf, D. (2020). Selective and cross-reactive SARS-COV-2 T cell epitopes in unexposed humans. *Science*, *370*(6512), 89–94. https://doi.org/10.1126/science.abd3871

Megasari, N. L., Utsumi, T., Yamani, L. N., Juniastuti, Gunawan, E., Furukawa, K., Nishimura, M., Lusida, M. I., & Mori, Y. (2021). Seroepidemiological study of SARS-COV-2 infection in East Java, Indonesia. *PLOS ONE*, *16*(5). https://doi.org/10.1371/journal.pone.0251234

Migliorini, F., Torsiello, E., Spiezia, F., Oliva, F., Tingart, M., & Maffulli, N. (2021). Association between HLA genotypes and covid-19 susceptibility, severity and progression: A comprehensive review of the literature. *European Journal of Medical Research*, *26*(1). https://doi.org/10.1186/s40001-021-00563-1

Milinski, M., Griffiths, S., Wegner, K. M., Reusch, T. B., Haas-Assenbaum, A., & Boehm, T. (2005). Mate choice decisions of stickleback females predictably modified by MHC peptide ligands. *Proceedings of the National Academy of Sciences*, *102*(12), 4414–4418. https://doi.org/10.1073/pnas.0408264102

Morens, D. M., Taubenberger, J. K., & Fauci, A. S. (2021). A centenary tale of two pandemics: The 1918 influenza pandemic and covid-19, part I. *American Journal of Public Health*, *111*(6), 1086–1094. https://doi.org/10.2105/ajph.2021.306310

Morens, D. M., Taubenberger, J. K., & Fauci, A. S. (2021). A centenary tale of two pandemics: The 1918 influenza pandemic and covid-19, part II. *American Journal of Public Health*, *111*(7), 1267–1272. https://doi.org/10.2105/ajph.2021.306326

Morens, D. M., Taubenberger, J. K., & Fauci, A. S. (2022). Universal coronavirus vaccines — an urgent need. *New England Journal of Medicine*, *386*(4), 297–299. https://doi.org/10.1056/nejmp2118468

Naqvi, A., Fatima, K., Mohammad, T., Fatima, U., Singh, I. K., Singh, A., Atif, S. M., Hariprasad, G., Hasan, G. M., & Hassan, M. I. (2020). Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach. *Biochimica et biophysica acta. Molecular basis of disease*, *1866*(10), 165878. https://doi.org/10.1016/j.bbadis.2020.165878

Nelde, A., Bilich, T., Heitmann, J. S., Maringer, Y., Salih, H. R., Roerden, M., Lübke, M., Bauer, J., Rieth, J., Wacker, M., Peter, A., Hörber, S., Traenkle, B., Kaiser, P. D., Rothbauer, U., Becker, M., Junker, D., Krause, G., Strengert, M., … Walz, J. S. (2020). Sars-cov-2-derived peptides define heterologous and covid-19-induced t cell recognition. *Nature Immunology*, *22*(1), 74–85. https://doi.org/10.1038/s41590-020-00808-x

Newman, J. A., Douangamath, A., Yadzani, S., Yosaatmadja, Y., Aimon, A., Brandão-Neto, J., Dunnett, L., Gorrie-stone, T., Skyner, R., Fearon, D., Schapira, M., von Delft, F., & Gileadi, O. (2021). Structure, mechanism and crystallographic fragment screening of the SARS-COV-2 NSP13 helicase. *Nature Communications*, *12*(1). https://doi.org/10.1038/s41467-021-25166-6

Nguyen, A., David, J. K., Maden, S. K., Wood, M. A., Weeder, B. R., Nellore, A., & Thompson, R. F. (2020). Human leukocyte antigen susceptibility map for severe acute respiratory syndrome coronavirus 2. *Journal of Virology*, *94*(13). https://doi.org/10.1128/jvi.00510-20

Pacholczyk, M., & Rieske, P. (2020). In silico studies suggest T-cell cross-reactivity between SARS-COV-2 and less dangerous coronaviruses. https://doi.org/10.21203/rs.3.rs-73773/v1

Pan, Y., Jiang, X., Yang, L., Chen, L., Zeng, X., Liu, G., Tang, Y., Qian, C., Wang, X., Cheng, F., Lin, J., Wang, X., & Li, Y. (2021). SARS-COV-2-specific immune response in COVID-19 convalescent individuals. *Signal Transduction and Targeted Therapy*, *6*(1). https://doi.org/10.1038/s41392-021-00686-1

Poland, G. A., Ovsyannikova, I. G., & Kennedy, R. B. (2020). SARS-CoV-2 immunity: Review and applications to Phase 3 vaccine candidates. *The Lancet*, *396*(10262), 1595–1606. https://doi.org/10.1016/s0140-6736(20)32137-1

Rahman, M. T., Sobur, M. A., Islam, M. S., Ievy, S., Hossain, M. J., El Zowalaty, M. E., Rahman, A. T., & Ashour, H. M. (2020). Zoonotic Diseases: Etiology, Impact, and Control. *Microorganisms*, *8*(9), 1405. https://doi.org/10.3390/microorganisms8091405

Rastogi, M., Pandey, N., Shukla, A., & Singh, S. K. (2020). SARS coronavirus 2: From genome to infectome. *Respiratory Research*, *21*(1). https://doi.org/10.1186/s12931-020-01581-z

Reynisson, B., Barra, C., Kaabinejadian, S., Hildebrand, W. H., Peters, B., & Nielsen, M. (2020). Improved prediction of MHC II antigen presentation through integration and motif deconvolution of mass spectrometry MHC eluted ligand data. *Journal of Proteome Research*, *19*(6), 2304–2315. https://doi.org/10.1021/acs.jproteome.9b00874

Roche, P. A., & Furuta, K. (2015). The ins and outs of MHC class II-mediated antigen processing and presentation. *Nature Reviews Immunology*, *15*(4), 203–216. https://doi.org/10.1038/nri3818

Salamanna, F., Maglio, M., Landini, M. P., & Fini, M. (2020). Body localization of ace-2: On the trail of the keyhole of SARS-COV-2. *Frontiers in Medicine*, *7*. https://doi.org/10.3389/fmed.2020.594495

Sette, A., & Crotty, S. (2020). Pre-existing immunity to sars-cov-2: The knowns and unknowns. *Nature Reviews Immunology*, *20*(8), 457–458. https://doi.org/10.1038/s41577-020-0389-z

Shah, V. K., Firmal, P., Alam, A., Ganguly, D., & Chattopadhyay, S. (2020). Overview of immune response during SARS-COV-2 infection: Lessons from the past. *Frontiers in Immunology*, *11*. https://doi.org/10.3389/fimmu.2020.01949

Shu, T., Huang, M., Wu, D., Ren, Y., Zhang, X., Han, Y., Mu, J., Wang, R., Qiu, Y., Zhang, D. Y., & Zhou, X. (2020). SARS-Coronavirus-2 Nsp13 Possesses NTPase and RNA Helicase Activities That Can Be Inhibited by Bismuth Salts. *Virologica Sinica*, *35*(3), 321–329. https://doi.org/10.1007/s12250-020-00242-1

Song, G., He, W.-ting, Callaghan, S., Anzanello, F., Huang, D., Ricketts, J., Torres, J. L., Beutler, N., Peng, L., Vargas, S., Cassell, J., Parren, M., Yang, L., Ignacio, C., Smith, D. M., Voss, J. E., Nemazee, D., Ward, A. B., Rogers, T., … Andrabi, R. (2021). Cross-reactive serum and memory B-cell responses to spike protein in SARS-COV-2 and endemic coronavirus infection. *Nature Communications*, *12*(1). https://doi.org/10.1038/s41467-021-23074-3

Stranzl, T., Larsen, M. V., Lundegaard, C., & Nielsen, M. (2010). NetCTLpan: pan-specific MHC class I pathway epitope predictions. *Immunogenetics*, *62*(6), 357–368. https://doi.org/10.1007/s00251-010-0441-4

Tan, C. C. S., Owen, C. J., Tham, C. Y. L., Bertoletti, A., van Dorp, L., & Balloux, F. (2020). Pre-existing t cell-mediated cross-reactivity to sars-cov-2 cannot solely be explained by prior exposure to endemic human coronaviruses. https://doi.org/10.1101/2020.12.08.415703

Tomita, Y., Sato, R., Ikeda, T., & Sakagami, T. (2020). BCG vaccine may generate cross-reactive T cells against SARS-COV-2: In silico analyses and a hypothesis. *Vaccine*, *38*(41), 6352–6356. https://doi.org/10.1016/j.vaccine.2020.08.045

Tomita, Y., Ikeda, T., Sato, R., & Sakagami, T. (2020). Association between HLA gene polymorphisms and mortality of COVID-19: An in silico analysis. *Immunity, Inflammation and Disease*, *8*(4), 684–694. https://doi.org/10.1002/iid3.358

Trougakos, I. P., Stamatelopoulos, K., Terpos, E., Tsitsilonis, O. E., Aivalioti, E., Paraskevis, D., Kastritis, E., Pavlakis, G. N., & Dimopoulos, M. A. (2021). Insights to SARS-COV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications. *Journal of Biomedical Science*, *28*(1). https://doi.org/10.1186/s12929-020-00703-5

Vardhana, S., Baldo, L., Morice, W. G., & Wherry, E. J. (2022). Understanding T-cell responses to covid-19 is essential for informing Public Health Strategies. *Science Immunology*. https://doi.org/10.1126/sciimmunol.abo1303

Vita, R., Mahajan, S., Overton, J. A., Dhanda, S. K., Martini, S., Cantrell, J. R., Wheeler, D. K., Sette, A., & Peters, B. (2018). The Immune Epitope Database (IEDB): 2018 update. *Nucleic Acids Research*, *47*(D1). https://doi.org/10.1093/nar/gky1006

Wang, F., Huang, S., Gao, R., Zhou, Y., Lai, C., Li, Z., Xian, W., Qian, X., Li, Z., Huang, Y., Tang, Q., Liu, P., Chen, R., Liu, R., Li, X., Tong, X., Zhou, X., Bai, Y., Duan, G., … Liu, L. (2020). Initial whole-genome sequencing and analysis of the host genetic contribution to COVID-19 severity and susceptibility. *Cell Discovery*, *6*(1). https://doi.org/10.1038/s41421-020-00231-4

Wieczorek, M., Abualrous, E. T., Sticht, J., Álvaro-Benito, M., Stolzenberg, S., Noé, F., & Freund, C. (2017). Major histocompatibility complex (MHC) class I and MHC class II proteins: Conformational plasticity in antigen presentation. *Frontiers in Immunology*, *8*. https://doi.org/10.3389/fimmu.2017.00292

World Health Organization. (2022). *WHO coronavirus (COVID-19) Dashboard*. World Health Organization. Retrieved May 18, 2022, from https://covid19.who.int/ .

World Health Organization. (2022). *Tracking sars-COV-2 variants*. World Health Organization. Retrieved May 18, 2021, from https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/.

Yoo, J.-S., Sasaki, M., Cho, S. X., Kasuga, Y., Zhu, B., Ouda, R., Orba, Y., de Figueiredo, P., Sawa, H., & Kobayashi, K. S. (2021). SARS-COV-2 inhibits induction of the MHC class I pathway by targeting the STAT1-IRF1-nlrc5 axis. *Nature Communications*, *12*(1). https://doi.org/10.1038/s41467-021-26910-8

Yoshimoto, F. K. (2020). The proteins of severe acute respiratory syndrome coronavirus-2 (SARS COV-2 or N-COV19), the cause of covid-19. *The Protein Journal*, *39*(3), 198–216. https://doi.org/10.1007/s10930-020-09901-4

Zhang, S.-fen, Tuo, J.-ling, Huang, X.-bin, Zhu, X., Zhang, D.-mei, Zhou, K., Yuan, L., Luo, H.-jiao, Zheng, B.-jian, Yuen, K.-yung, Li, M.-feng, Cao, K.-yuan, & Xu, L. (2018). Epidemiology characteristics of human coronaviruses in patients with respiratory infection symptoms and phylogenetic analysis of HCoV-OC43 during 2010-2015 in Guangzhou. *PLOS ONE*, *13*(1). https://doi.org/10.1371/journal.pone.0191789

Zhang, Y., Su, L., Chen, Y., Yu, S., Zhang, D., Mao, H., & Fang, L. (2021). Etiology and clinical characteristics of SARS-COV-2 and other human coronaviruses among children in Zhejiang Province, China 2017–2019. *Virology Journal*, *18*(1). https://doi.org/10.1186/s12985-021-01562-8

Zhao, J., Cui, W., & Tian, B.-ping. (2020). The potential intermediate hosts for SARS-COV-2. *Frontiers in Microbiology*, *11*. https://doi.org/10.3389/fmicb.2020.580137

Zhao, X., Ding, Y., Du, J., & Fan, Y. (2020). 2020 update on human Coronaviruses: One health, One world. *Medicine in Novel Technology and Devices*, *8*, 100043. https://doi.org/10.1016/j.medntd.2020.100043

Zhao, J., Zhao, J., Mangalam, A. K., Channappanavar, R., Fett, C., Meyerholz, D. K., Agnihothram, S., Baric, R. S., David, C. S., & Perlman, S. (2016). Airway memory cd4 + t cells mediate protective immunity against emerging respiratory coronaviruses. *Immunity*, *44*(6), 1379–1391. https://doi.org/10.1016/j.immuni.2016.05.006

Zheng, J. (2020). SARS-CoV-2: an emerging coronavirus that causes a global threat. International Journal of biological sciences, 16(10), 1678.